Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
1999
Cremophor EL and Paclitaxel Pharmacokinetics
publication
Evidence: moderate
Author Information
Author(s): Tellingen O van, Huizing M T, Panday V R Nannan, Schellens J H M, Nooijen W J, Beijnen J H
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Does Cremophor EL play a role in the non-linear pharmacokinetics of paclitaxel in patients?
Conclusion
Cremophor EL causes non-linear pharmacokinetics of paclitaxel in patients, suggesting a need to re-evaluate previous pharmacokinetic assumptions.
Supporting Evidence
- The pharmacokinetics of Cremophor EL was non-linear with lower clearance in shorter infusion schedules.
- Maximum plasma levels of paclitaxel were significantly higher in 3-hour infusions compared to longer durations.
- Cremophor EL was not found in the ultrafiltrate fraction, indicating its role in trapping paclitaxel.
Takeaway
This study found that a substance called Cremophor EL affects how a cancer drug called paclitaxel works in the body, making it behave differently than expected.
Methodology
The pharmacokinetics of paclitaxel and Cremophor EL were established in patients receiving different infusion durations.
Statistical Information
P-Value
0.035
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website